Last updated: 07/17/2024 17:47:08
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Clinical evaluation of 323U66 SR in patients with depression - Placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors
Trial description: This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Change from baseline in the Hamilton Depression Scale (HAM-D 17 items) total score
Timeframe: Baseline and Week 12
Secondary outcomes:
Hamilton Depression Scale (HAM-D 17 items) total score
Timeframe: Week 8 and Week 12
Change from baseline in the Hamilton Depression Scale (HAM-D 17 items) total score at Week 8 and total score at Week 12
Timeframe: Baseline to Week 8 and Week 12
Percentage of change from baseline of the Hamilton Depression (HAM-D 17 items) total score at Weeks 8 and 12.
Timeframe: Baseline to Week 8 and Week 12
Percentage of responders based on Hamilton Depression (HAM-D 17 items) Scale total score at Weeks 8 and 12
Timeframe: Baseline to Week 8 and Week 12
Percentage of Remitters based on Hamilton Depression (HAM-D 17 items) Scale total score at Weeks 8 and 12
Timeframe: Baseline to Week 8 and Week 12
Change From Baseline in Each Item of the Hamilton Depression Scale (HAM-D 17 Items) Score at Weeks 8 and 12
Timeframe: Baseline to Week 8 and Week 12
Percentage of Change From Baseline in Each Item of the Hamilton Depression Scale (HAM-D 17 Items) Score at Weeks 8 and 12
Timeframe: Baseline to Week 8 and Week 12
Change from Baseline in Clinical Global Impressions - Severity of illness (CGI-S) scale at Weeks 1, 2, 3, 4, and 8 and 12
Timeframe: Baseline to Weeks 1, 2, 3, 4, 8, and 12
Percentage of Responders Based on the Clinical Global Impression - Global Improvement (CGI-I) Scale at Weeks 8 and 12
Timeframe: Baseline to Week 8 and Week 12
Study Continuation Rate as assessed by the number of participants at risk at Week 12
Timeframe: Week 12
Safety: Adverse events by Organ System Class, Intensity, and Frequency
Timeframe: Baseline to Week 12
Interventions:
Enrollment:
325
Primary completion date:
2008-28-03
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Depressive Disorder
Product
bupropion, paroxetine
Collaborators
Not applicable
Study date(s)
January 2006 to March 2008
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- [At the start of the pretreatment phase]
- Target disease: Patients diagnosed as having the following primary disease on the basis of DSM-IV-TR criteria.
- [At the start of the pre-treatment phase]
- Patients with a complication of glaucoma
Inclusion and exclusion criteria
Inclusion criteria:
- [At the start of the pretreatment phase]
- Target disease: Patients diagnosed as having the following primary disease on the basis of DSM-IV-TR criteria. -Major Depressive Disorder, Single Episode (296.2x) (excluding with psychotic features) -Major Depressive Disorder, Recurrent (296.3x) (excluding with psychotic features)
- HAM-D (17 items) total score is >=16.
- Patients who have been treated with marketed paroxetine (Paxil®) at 20mg/day to 40mg/day for 4 weeks and more at the start of the pretreatment phase.
- Age: >=18 years old (at the time of informed consent) , <65 years old (at the start of treatment phase )
- Gender: Male or female.
- Inpatients or outpatients: Either
- Informed consent: The subject himself/herself must give written informed consent. However, if the subject is under 20 at the time of giving consent, both the subject himself/herself and his/her legally acceptable representative must give written informed consent. [At the end of the pretreatment phase] 1. HAM-D (17 items) total score is ≥14. 2. Percentage of change from the start of the pretreatment phase in the HAM-D (17 items) total score is <50% [At the start of the treatment phase] 1. HAM-D (17 items) total score is ≥14. 2. Percentage of change from the start of the pretreatment phase in the HAM-D (17 items) total score is <50%
Exclusion criteria:
- [At the start of the pre-treatment phase]
- Patients with a complication of glaucoma
- Patients concomitantly using a drug increasing the risk of bleeding and patients with bleeding tendency or predisposition to bleeding
- Patients with predisposition to seizure (who currently have or have a past history of seizure, febrile convulsive seizure in infancy, cerebral tumour, cerebrovascular disorder or head injury, who have a family history of idiopathic seizure, patients with diabetes who have been treated with oral hypoglycaemics or insulin, or who use drugs lowering the threshold of seizure).
- Patients who currently have or have a past history of the following disorders:
- Anorexia nervosa (DSM-IV-TR 307.1)
- Bulimia nervosa (DSM-IV-TR 307.51)
- Patients with a history of manic episode
- Patients with a past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder
- Patients with a current DSM-IV-TR Axis II diagnosis (e.g., antisocial or borderline personality disorder)
- Patients starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) and formal cognitive behaviour therapy within 5 weeks prior to the start of the pre-treatment phase
- Patients with a diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria or with a diagnosis of substance dependence within 1 year prior to the start of the pre-treatment phase
- Patients who have received electroconvulsive therapy within 17 weeks prior to the start of the pre-treatment phase
- Patients who have taken MAO inhibitors (selegiline hydrochloride) within 2 weeks prior to the start of the pre-treatment phase
- Patients who have taken another investigational drug within 12 weeks prior to the start of the pre-treatment phase
- Female patients who are pregnant, possibly pregnant or are nursing, and those who want to become pregnant before 30 days after the last dose of the investigational product
- Patients who have attempted suicide within 17 weeks prior to the start of the pre-treatment phase, or patients for whom the score of suicide-related item No. 3 of HAM-D is >=3, or patients in whom the risk of suicide is judged to be high by the investigator (sub-investigator)
- Patients in whom the risk of homicide is judged to be high by the investigator (sub-investigator)
- Patients with a history of hypersensitivity to 323U66 and/or paroxetine
- Patients with serious cerebral disease
- Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) feels may predispose the subject to ischemia or arrhythmia
- Patients with serious physical symptoms (i.e. cardiac/hepatic/renal disorder, hematopoietic disorder) The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992).
- Patients with a history or complication of cancer or malignant tumour.
- Patients whose major depressive disorder is due to direct physiological effects of a general medical condition (for example, hypothyroidism, Parkinson's disease, chronic pain)
- Patients with systolic blood pressure of >=160 mmHg or diastolic blood pressure of >=100 mmHg
- Patients who are inappropriate for participating in the study in the judgement of the investigator (sub-investigator) [At the start of the treatment phase] 1. Patients whose compliance of paroxetine during the pretreatment phase is less than 70%. 2. Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) feels may predispose the subject to ischemia or arrhythmia 3. Patients with systolic blood pressure of >=160 mmHg or diastolic blood pressure of >=100 mmHg
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2008-28-03
Actual study completion date
2008-28-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website